Document resource
Background and Importance Chimeric antigen receptor T-cell(CAR T-cell) therapies have demonstrated effectiveness in hematologic malignancies in pivotal trials. However, real-world evidence remains limited.Aim and Objectives To describe real-world-clinical-outcomes and the toxicity profile of CAR-T-cell therapy at a tertiary hospital.Material and Methods Retrospective analysis of patients treated with commercial CAR-T between July 2022 and March 2025. Variables collected included comercial CAR-T, age, sex, diagnosis, ECOG, prior lines of therapy, disease status and prior transplantation.Outcomes analysed were overall response rate (ORR), complete remission (RC), partial remission (RP) and progression-free survival (PFS) at +30, +90 days and 6 months, cytokine release syndrome (CRS), immune-effector-cell-associated-neurotoxicity-syndrome (ICANS), Intensive Care Unit (ICU) admission and median stay, prolonged cytopenias (>30 days post-CAR-T) and length of hospitalisation.Results Baseline characteristics: 34 patients received commercial CAR T-cell therapy.Axicabtagén ciloleucel(Yescarta ) was administered in 80.8%, brexucabtagén autoleucel(Tecartus ) in 11.5%, and Tisagenlecleucel(Kymriah ) in 7.7 % of patients. The median age was 67.5 years (IQR 58.8– 72.0), and 73% were male.The diagnoses were diffuse large B-cell lymphoma (DLBCL) in 82.4%, mantle cell lymphoma (MCL) in 14.7%, and primary mediastinal large B-cell lymphoma (LBMP) in 2.9% of patients.ECOG performance status was 0 in 80.8%, 1 in 15.4%, and 2 in 3.8% of patients.Patients had received the following number of prior lines of therapy: 1 line (11.5%), 2 lines (73.1%), and ≥3 lines (15.4%). 69.2% of patients had progressive disease and 30.8% relapsed disease. Prior transplantation was performed in 30.8% of patients. Effectiveness Day +30: ORR 92.3% (CR 57.7%, PR 34.6%), PFS 91,2%Day +90: ORR 61.5% (CR 50.0%, PR 11.5%), PFS 70,6%Month +6: ORR 50.0% (CR 46.2%, PR 3.8%), PFS 64,7% Safety All patients developed CRS (23.1% grade I, 61.5% grade II, and 15.4% grade III). ICANS occurred in 53.8% (26.9% grade I, 7.7 % grade II, 7.7 % grade III, and 11.5 % grade IV). 65.4% required ICU admission (median stay:3 days ; IQR 3– 10). Prolonged cytopenias were documented in 28% of patients. The median length of hospitalisation was 23.5 days (IQR 17-28).Conclusion and Relevance CAR T-cell therapy in real-world-practice achieves high early response rates, although effectiveness decreases over time. Toxicity remains a significant challenge, particularly CRS and ICANS, underscoring the need for optimised supportive care and long-term follow-up strategies.Conflict of Interest No conflict of interest